Punta Indratomo
DataHelix, Jogyakarta, Indonesia

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

PSEUDOURIDINE AND N1-METHYLPSEUDOURIDINE IN mRNA VACCINES MODULATE RETINOIC ACID INDUCIBLE GENE I (RIG-I) AND TOLL-LIKE RECEPTORS (TLR) ACTIVATION Ni Wayan Erly Sintya Dewi; Fatiha Khairunnisa; Nita Cahyawati; Muhammad Miftahussurur; Punta Indratomo
Meditory : The Journal of Medical Laboratory Vol. 13 No. 2 (2025): Meditory, Volume 13 No. 2 Tahun 2025
Publisher : Jurusan Teknologi Laboratorium Medis, Poltekkes Kemenkes Denpasar

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33992/meditory.v13i2.4781

Abstract

Background: The advent of mRNA vaccines has underscored the significance of nucleoside modifications in regulating innate immune recognition. Pseudouridine (Ψ) and its derivative, N1-methylpseudouridine (m1Ψ), are widely used to enhance the efficacy and safety of mRNA vaccines.Objective: This review examines how Ψ and m1Ψ alter the activation of key innate immune sensors, including RIG-I, MDA5, and endosomal Toll-like receptors (TLR3, TLR7, TLR8).Methods: A narrative review was conducted using PubMed, Scopus, and Web of Science databases, focusing on studies evaluating the molecular and immunological effects of Ψ and m¹Ψ on innate immune sensors.Discussion: Incorporation of Ψ or m1Ψ in mRNA markedly suppresses activation of TLR3, TLR7, and TLR8. Ψ-containing RNA avoids detection by TLR7/8 via two mechanisms: it resists endosomal nuclease digestion into immunostimulatory fragments and is poorly recognized by the TLR7/8 ligand-binding sites. m1Ψ similarly evades nuclease processing yet, unlike Ψ, can directly activate TLR8. In the cytosol, Ψ/m1Ψ modifications strongly reduce RIG-I signaling without impeding MDA5. Conclusions: By limiting innate PRR activation, these modifications increase the translation and stability of mRNA vaccines while reducing inflammatory interferon responses. This immune evasion is crucial for the high efficacy and tolerability of current mRNA vaccines; however, a trade-off exists between minimizing reactogenicity and the adjuvant benefits of innate stimulation.